|
|
Elevated
levels of alpha-2-Heremans-Schmid glycoprotein in CSF of patients with
low-grade gliomas
Ribom
D, Westman-Brinkmalm A, Smits A, Davidsson P
Department of Neuroscience, Neurology, University Hospital,
Uppsala, Sweden. dan.ribom@neurologi.uu.se
Little is known about the expression of mitogens and other
tumour-related substances in the cerebrospinal fluid (CSF) of glioma
patients.
The
aim of the current study was to determine the presence of aberrant
proteins in the CSF of patients with low-grade gliomas.
Lumbar
puncture was performed in 8 adult patients with supratentorial
low-grade gliomas at the time of diagnosis and in 7 controls.
Two-dimensional
gel electrophoresis and matrix-assisted laser desorption/ionisation
time of flight mass spectrometry were used to detect and quantify
deviant proteins in the CSF.
Two
isoforms of alpha(2)-Heremans-Schmid glycoprotein (AHSG) were
identified and demonstrated in higher levels in patients with
low-grade gliomas compared with the control group consisting of
patients with mixed neurological diagnoses (p = 0.001 and p = 0.04,
respectively).
In
1 patient, the level of AHSG was significantly reduced after gross
total resection of the tumour.
AHSG
appears in the present proteome screening as a novel substance in
glioma research.
This
glycoprotein is expressed in the fetal human brain and is believed to
be involved in the embryonic development of the neocortex.
Further
analyses are planned to determine the significance of the increased
levels of AHSG in the CSF of patients with low-grade gliomas.
Copyright
2003 S. Karger AG, Basel
PMID: 12853704 [PubMed - indexed for MEDLINE]
|
